Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Paul Kim, Paul M. Garofolo, Robert W. McKee et al.|The Lancet Infectious Diseases|2024

Cited by 83